New Treatments and Targets in Pulmonary Hypertension
June 19 - 20, 2014
At the Scientific Sessions at PHA’s International PH Conference, researchers and medical professionals will have the opportunity to engage in educational sessions about PH practice and cutting-edge research. This year’s topic, New Treatments and Targets in Pulmonary Hypertension, features PH experts who will share the latest developments in PH treatment and research. The Scientific Sessions will also feature a presentation of abstract posters and free-form panel discussions about the top abstracts.
After participating in this activity, participants will be able to:
- Discuss future drug targets in Group I and COPD-associated pulmonary hypertension.
- Discuss limitations of current trial designs in pulmonary arterial hypertension.
- Describe future treatment of BMPR2 mutation in pulmonary arterial hypertension.
Scientific Sessions Schedule and Speakers
Scientific Sessions Poster Hall Reception
Thursday, June 19, 5:30-7:30 p.m.
Join your colleagues to view abstracts in the poster hall.
Scientific Sessions: New Treatments and Targets in PH
Friday, June 20, 8 a.m. - 7:30 p.m.
High Throughput Drug Screening in PAH: From Cells to People
Edda Spiekerkoetter, MD, Stanford University, Stanford, Calif.
Roham Zamanian, MD, FCCP, Stanford University, Stanford, Calif.
NOS Inhibition in COPD – Potential Therapeutics for Group III PH?
Norbert Weissmann, PhD, University of Giessen, Giessen, Germany
Nitric Oxide Therapeutics in Pulmonary Vascular Disease
Marc Simon, MD, MS, FACC, University of Pittsburgh Medical Center, Pittsburgh, Pa.
Clinical Trial Design in Pulmonary Vascular Disease in Adults – Panel Discussion
Panelists will include:
Richard Channick, MD, Massachusetts General Hospital, Boston, Mass.
Tim Moore, MD, PhD, NHLBI, Bethesda, Md.
Mardi Gomberg-Maitland, MD, MSc, University of Chicago, Chicago, Ill.
Metabolic Derangements in PH – Dichloracetate Studies
Evangelos Michelakis, MD, University of Alberta, Edmonton, Canada
Trials in Pediatric PH: Specific Concerns in Design and Endpoints
Dunbar Ivy, MD, Children’s Hospital Colorado, Aurora, Colo.
Future Therapies in PAH – Update on the New Landscape and Drugs in the Pipeline
Ioana Preston, MD, Tufts-New England Medical Center, Boston, Mass.